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and is a required co-factor for many types of fibroblast
growth factor (FGF) signaling in vitro. We report that some
HSs, when added exogenously to the developing Xenopus
optic pathway, severely disrupt target recognition causing
axons from the retina to bypass their primary target, the
optic tectum. Significantly, HS sidechains from a neuro-
epithelial perlecan variant that preferentially bind FGF-2,
HS(FGF-2), cause aberrant targeting, whereas those that
preferentially bind FGF-1 do not. Charge-matched
fragments of HS(FGF-2) show that the mistargeting
activity associates with the FGF-binding fragments. Hepar-
itinase removal of native HSs at the beginning of optic tract
formation retards retinal axon elongation; addition of
FGF-2 restores axon extension but axons lose directional-
ity. Late HS removal, after axons have extended through
the tract, elicits a tectal bypass phenotype indicating a
growth promoting and guidance function for native HSs.
Our results demonstrate that different HS sidechains from
the same core protein differentially affect axon growth in
vivo, possibly due to their distinct FGF-binding prefer-
ences, and suggest that growth factors and HSs are
important partners in regulating axon growth and
guidance in the developing visual system.
Key words: FGF-2, FGF receptor, retinal axons, tectum, axon
guidance, Xenopus
SUMMARYINTRODUCTION
When axons from the retina reach the diencephalic/midbrain
border, they depart from other axon tracts and selectively enter
their target, the optic tectum. This process of target recogni-
tion is an essential early step in establishing functional visual
connections and relies on the ability of growth cones at the tips
of advancing axons to detect and respond to cues patterning
the neuroepithelial substrate. Although the molecular events
underlying this behavior are not well characterized, recent
evidence implicates the fibroblast growth factor receptor
(FGFR) and FGF-2 in the Xenopus visual system. Disruption
of FGF signaling in growing retinal ganglion cell (RGC) axons
by dominant negative FGFR inhibition and by exogenous FGF-
2 causes target recognition defects in which affected axons
bypass the tectum (McFarlane et al., 1995, 1996). A third and
crucial co-factor for many FGF-FGFR interactions is heparan
sulfate (Yayon et al., 1991). Here we have asked whether HS
also plays a role in retinal axon guidance by interfering with
HS function in a living brain preparation. 
HS proteoglycans (HSPGs) are widely expressed in the
embryonic brain and their expression is developmentally
regulated (Halfter, 1993; Herndon and Lander, 1990;
Nurcombe et al., 1993; Oohira et al., 1994; Teel and Yost,1996). Free HS sidechains potently affect neuronal differen-
tiation in a variety of assays, implicating a functional role for
endogenous HSPGs. For example, HS alters the characteristics
of neurite outgrowth from neurons in vitro (Dow et al., 1991;
Giuseppetti et al., 1994; Haugen et al., 1992a; Isahara and
Yamamoto, 1995; Verna et al., 1989), while exogenous HS or
enzymatic removal of endogenous HS disrupts axon navigation
in the developing cockroach limb (Wang and Denburg, 1992).
In addition, HS sidechains from rat brain N-syndecan, an
HSPG, inhibit the neurite outgrowth promoting activity of the
heparin-binding growth-associated molecule (HB-GAM;
Kinnunen et al., 1996).
HS sidechains can bind to a variety of cell surface and extra-
cellular matrix (ECM) proteins, including those known to
stimulate neurite outgrowth (Cole et al., 1986; Haugen et al.,
1990; Kinnunen et al., 1996; Lander, 1990), and can potenti-
ate the activities of various secreted factors (Bradley and
Brown, 1990; Burgess and Maciag, 1989; Serafini et al., 1994;
Wanaka et al., 1993). The interactions between HS and the
FGF family of heparin-binding growth factors are particularly
well documented. The biological activities of FGF-1 and FGF-
2 depend on their ability to bind cell surface or extracellular
matrix HS (Klagsbrun and Baird, 1991; Schlessinger et al.,
1995). Cells that express the high affinity FGFRs, but lack HS,
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Yayon et al., 1991). By binding and delivering FGFs to their
high affinity tyrosine kinase FGFR, HSPGs act as co-receptors
and are often referred to as low affinity FGFRs (Kiefer et al.,
1991; Schlessinger et al., 1995; Spivak-Kroizman et al., 1994).
In addition, HSPGs are thought to increase local concentrations
of FGF by sequestering and protecting it from degradation
(Gospodarowicz and Cheng, 1986).
Recent evidence shows that some types of HS chains contain
defined carbohydrate sequences that bind preferentially to
FGF-2 (Gallagher and Turnbull, 1992; Ornitz et al., 1995;
Rusnati et al., 1994). By adding modified HS sidechains to the
same core protein, a perlecan-like HSPG (HSPG-PRM) in the
mouse brain neuroepithelium switches its binding affinity from
FGF-2 to FGF-1 within a 2-day period of embryonic develop-
ment (E9-E11; Ford et al., 1994; Nurcombe et al., 1993; Joseph
et al., 1996). This switch coincides with the transition that the
neuroepithelium undergoes from mitogenesis to the beginning
of neuronal differentiation and suggests that developmentally
regulated glycosylations of HS side chains can intricately
regulate FGF signaling in the developing CNS (Nurcombe et
al., 1993). The differential growth factor binding characteris-
tics of HS might account for the finding that some brain-
derived HSs potentiate the activity of FGF-2, while others
prevent FGF-2 binding to its receptor (Guimond et al., 1993;
Hondermarck et al., 1992). Thus, by regulating the availability
and biological activity of FGFs, and possibly other heparin-
binding factors, HSPGs might help to localize signals
important for axon growth and guidance.
In the present study we have disrupted native HS function
in vivo by adding different types of HS exogenously and by
removing endogenous HS. Our results indicate that HS is
important for two aspects of retinal axon growth, elongation in
the optic tract and tectal targeting. This dual functional role is
similar to that previously identified for the FGFR (McFarlane
et al., 1996) and is consistent with a model in which the acti-
vation of FGFRs on retinal growth cones is regulated by
specific interactions with native HS and FGF-2 that pattern the
neuroepithelial substrate. Additionally, our results suggest that
guidance in the optic tract involves an HS-dependent
mechanism.
MATERIALS AND METHODS
Embryos
Xenopus laevis embryos were obtained from hormone-induced
matings of adult frogs and in vitro fertilization according to standard
procedures (Gimlich and Gerhart, 1984; Gurdon, 1977). Embryos
were raised in 10% Holtfreter’s solution; the temperature was varied
between 14°C and 27°C to control their speed of development.
Staging was according to the normal tables of Nieuwkoop and Faber
(1967). Motile embryos were anesthetized with tricaine (ethyl-3-
aminobenzoate methanesulfonic acid; Aldrich) for experimental
manipulations.
Exposed brain preparation and labeling of retinal
projections
Exposed brain experiments were performed as described previously
(Chien et al., 1993). Surgical procedures were carried out in 100%
modified Ringers (MR; Gimlich and Gerhart, 1984). In a typical
experiment, stage 32 embryos were immobilized by pinning in aSylgard Petri dish and the epidermis and eye were removed from the
left side of the head; the embryos were then transferred to experi-
mental or control solutions and allowed to develop to stage 40
(approximately 26 hours). The times of initial brain exposure (stage
32-35/56) and fixation (stage 37/38 to 40) were varied depending on
the particular experiment. Experimental and control solutions were
80% modified Ringers with HSs or HS-degrading enzymes added to
the experimental solution.
Retinal axons from the remaining right eye were anterogradely
labeled with horseradish peroxidase (HRP; type VI; Sigma) as
described previously (Cornel and Holt, 1992). For whole-mount visu-
alization of the optic projection, brains were dissected out of the
embryos after fixation (1% glutaraldehyde), reacted with diaminoben-
zidine (DAB; Sigma), and mounted projection side up in Coverbond
(BSP) with a coverslip supported by two reinforcement rings (Avery).
For fluorescent immunohistochemistry, embryos were fixed in 4%
paraformaldehyde at 4°C overnight and sectioned at 12 m m on a Leitz
cryostat. Drawings of HRP-filled projections were made with a
camera lucida attached to a Zeiss photomicroscope and scanned using
a ScanJet IIc (Hewlett-Packard) to obtain digital images. Quantitation
of projection length and width was done using NIH Image and macros
to normalize brain size (see Chien et al., 1993; McFarlane et al.,
1995). 
Reagents
The following reagents were used: heparin, HS from bovine mucosa
(Sigma); heparitinase (Seikagaku) at 0.25-0.5 U/ml with no protease
inhibitors added. HS(FGF-2) and HS(FGF-1) were isolated from
mouse E10 neuroepithelial-derived 2.3D tissue culture medium as
described previously (Brickman et al., 1995; Ford et al., 1994; Joseph
et al., 1996; Nurcombe et al., 1993) broadly following the techniques
of Turnbull and Gallagher (1990). HS(FGF-2) fragments were
prepared by spiking the sample with previously isolated tritiated
HS(FGF-2) and subsequently partially digesting with heparitinase
(0.25 U enzyme for 2 hours at 37°C). The reaction was stopped by
boiling and the sample subjected to size exclusion chromatography on
a Bio-Gel P10 column (1 cm · 120 cm; Bio Rad Laboratories) in 0.2
M ammonium bicarbonate buffer. The pools of different sized
fragments were detected by scintillation counting. Each pool of
similarly sized fragments was isolated and the sizes of interest rechro-
matographed to ensure size homogeneity. Equivalent charge density
was ensured by running all of the fragments over anionic exchange
columns as previously described (Nurcombe et al., 1993) and step-
eluting at 0.4 M NaCl. The pools containing the 18-mers and the 16-
mers were desalted by freeze drying and exposed to an FGF-2 affinity
column (Affi-Gel 10; Bio Rad). The non-binding fractions were those
released below 0.5 M NaCl and the fraction released above 1.0 M
NaCl was considered to be the binding fraction.
Suramin (a gift from Dr D. Donaghue) was added to exposed brains
at 10 µM. For mitotic labeling, stage 40 experimental embryos were
injected abdominally with 5 mg/ml BrdU (Sigma), fixed 3 hours later,
and processed according to standard procedures. To assess cell
viability in the brain, 1% Trypan blue (Sigma) in MR was added to
heparin-treated embryos for 1 hour. Embryos were fixed in 4%
paraformaldehyde overnight at 4°C, and dead cells were identified in
wholemounted brains. ApopTag Plus in situ apoptosis detection kit
(Oncor Inc.) was used for analysis of apoptosis in the retina following
heparitinase treatment (0.25-0.5 U/ml between stages 33/34 and 40).
Immunohistochemistry
Fixed embryos were embedded in OCT (Miles) and cryostat sectioned
at 12 µm. For single antibody labeling, sections were washed with
PBT (phosphate-buffered saline, 0.2% BSA fraction V (Fisher Scien-
tific), 0.5% Triton X-100 (Sigma) pH 7.4), blocked in PBT contain-
ing 5% normal goat serum, and incubated overnight in primary
antibody at 4˚C followed by fluorescein-conjugated secondary
antibody. To visualize RGC axons and HS together, sections from
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Fig. 1. Pattern of native HS staining in the embryonic optic pathway.
Confocal micrographs of transverse sections of the embryonic brain
(left side) immunostained for HS using HepSS-1 antibody. (A) HS
immunostaining is localized to a narrow band close to the pial
surface of the diencephalon (Di) at stage 35/36 and is not present in
the tectum (Tec). (B) Absence of HS staining following exposure of
optic tract to heparitinase from stage 32 to 40. (C,D) Double
immunolabeled section showing the earliest population of retinal
ganglion cell axons (red) growing in the HS-rich region (green) close
to the pial surface of the diencephalon. The rhodamine filter only was
used in C. Np, neuropil; on, optic nerve. Dorsal is up, lateral is left.
Scale bar, 100 m m (A,B) and 50 µm (C,D).HRP-filled embryos were double-labeled, first with an anti-HRP
antibody and rhodamine-conjugated secondary antibody and second
with an anti-HS primary and fluorescein-conjugated secondary
antibody. Sections were mounted in glycerol with an anti-bleaching
agent (0.1% paraphenylenediamine) and viewed with a Nikon Diaphot
200 inverted microscope attached to a Noran Odyssey confocal
scanning laser microscope. The color confocal images were combined
into double-labeled images using the Photoshop (Adobe Inc.) program
for Macintosh.
Primary antibodies used in this study include: HepSS-1 and 4H10
(Seikagaku; Kure and Yoshie, 1986; David et al., 1992) which
recognize a subset of HS chains at 1:200 dilution and an anti-HRP
polyclonal antibody (Sigma) from rabbit at 1:500 dilution; R5 which
labels radial glia cells (a gift from Dr U. Drager; Drager et al., 1984)
at 1:1; 6F11 which recognizes the extracellular domain of NCAM at
1:10 (Sakaguchi et al., 1989); 6-11B-1 which labels acetylated tubulin
(Sigma) at 1:200, an anti-BrdU monoclonal IgG antibody (Sigma)
from mouse at 1:1000. Secondary antibodies were from Jackson
ImmunoResearch Laboratories.
Retinal cultures
Eye primordia were dissected from stage 25 embryos and cultured as
described previously (Harris and Messersmith, 1992; McFarlane et al.,
1995). Dissociated cells were plated onto polyornithine/laminin-
coated coverslips in 35 mm Petri dishes containing 4 ml of L15 culture
medium (CORE cell culture facility, UCSD) supplemented with 0.1%
BSA fraction V in either the presence or absence of 20 ng/ml human
recombinant FGF-2 (GIBCO) and/or HS(FGF-2) at 1-1000 ng/ml.
Cultures were fixed after 24 hours in 1% glutaraldehyde for 45
minutes on ice. Mounted cultures were viewed with phase optics on
an inverted Nikon Diaphot 300 microscope and digital images were
captured using a CCD camera (Cohu). Neurite length was measured
using the NIH Image program for Macintosh. Only the longest
neurites of isolated cells were included.
125I-FGF-2 binding assays
Embryonic stage 40 brains were dissected and transferred into 50 µl
of 100% MR with 0.2% BSA containing either HSs or control car-
bohydrates. HSs included: 0.1 mg/ml heparin, 0.1 mg/ml FGF-2-
binding HS (HS(FGF-2)), 0.1 mg/ml FGF-1-binding HS (HS(FGF-
1)), and 0.1 mg/ml HS isolated from bovine mucosa (Sigma); control
carbohydrates included: 1 mg/ml chondroitin sulfate C and 1 mg/ml
sucrose. The brains were incubated for 3 hours at room temperature
with 15 ng/ml 125I-labelled FGF-2 (NEN DuPont, specific activity 144
m Ci/m g), washed 4 times with PBS containing 0.2% BSA fraction V,
transferred into new tubes, and counted in a scintillation counter.
RESULTS
HSs are present in the embryonic visual pathway
To determine whether HSs are present in the developing optic
tract, sections of Xenopus embryonic brains were immunola-
beled with two different anti-HS antibodies (HepSS-1 and
10E4) during the period when retinal axons first navigate
through the contralateral optic tract (stages 33/34 and 35/36)
and enter their target, the optic tectum (stages 37/38-40). Both
antibodies revealed similar expression patterns in the brain. In
the diencephalon, strong HS immunostaining was localized to
the ventral two thirds of the optic tract close to the pial surface
(Fig. 1A). This positive staining diminished in the dorsal brain
and was absent in the rostral optic tectum. The specificity of
the immunolabeling was tested by removing endogenous HS
with heparitinase (0.25-0.5 U/ml), a broad-spectrum mixture
of heparin lyase II and III which catalyzes the eliminativecleavage of N-acetyl-D-glucosaminide linkages. No HS
immunostaining was detectable following the enzyme
treatment (Fig. 1B). The HepSS-1 and 10E4 antibodies,
however, may only detect a subset of HSs, leaving open the
possibility that other types of HSs are expressed in immuno-
negative areas. Nonetheless, the observed expression pattern
demonstrates that certain HSs are present in the developing
optic pathway and that their expression diminishes near the
tectum.
To visualize HS expression in relation to the nascent retinal
projection, sections were double-labeled with antibodies
against HS and horseradish peroxidase (HRP) following
anterograde transport of HRP from the retina. Staining was
found to overlap within the superficial 10-20 µm of the ventral-
to-mid optic tract (Fig. 1C,D) where most retinal ganglion cell
(RGC) growth cones are positioned as they navigate through
this region. These axons are subsequently displaced interiorly
by later arriving growth cones (Holt, 1989). Thus, RGC axons
extend through an HS-rich region in the optic tract but enter an
HS-poor region when they reach the tectum. This distribution
of HS correlates with FGF-2 staining in the developing
pathway (McFarlane et al., 1995) suggesting the possibility
that these two molecules interact to regulate axon growth.
Exogenous HSs disrupt target recognition
To determine whether HSs are involved in RGC axon growth
and guidance, different types of HSs were applied to retinal
axons in exposed brains during the period when they first
navigate to and innervate the tectum. In these experiments, the
skin epidermis was removed from the left side of the embryos’
heads to expose the underlying developing optic tract at stage
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Fig. 2. Exogenously applied FGF-2-binding HS disrupts target
recognition. Lateral views of wholemount brains at stage 40 showing
the trajectories of HRP-filled optic projections. Brains were exposed
to different types of HSs at 0.1 mg/ml for a duration of 18-24 hours,
from stage 33/34 to 40. B,D,F are higher power views of A,C and E
respectively. (A,B) Control projection forms a defined optic tract (ot)
in the diencephalon (Di) and crosses smoothly into the tectum (Tec).
Dotted line and arrow demarcate the anterior tectal border.
(C,D) Projection exposed to heparin extends correctly through the
diencephalon but fails to enter the tectum. The projection bifurcates
at the entrance to the tectum and axons course dorsally and
posteriorly around the target. (E,F) Retinal axons growing in the
presence of the full length HS(FGF-2) veer dorsally at the tectal
border and bypass the tectum. (G) FGF-2-binding fragments of the
full length HS(FGF-2) also cause axons to grow past the target
without entering it, whereas (H) non-FGF-2-binding fragments of
HS(FGF-2) have no effect. Brains exposed to HS(FGF-1) (I) and to a
non-FGF-2-binding full length HS (J) have normal optic projections
that enter the tectum. Tel, telencephalon; dorsal is up, anterior to the
left. Scale bar, 200 m m in A,C and E and 100 m m in B,D and F-J.
Table 1. Percentage of optic projections showing bypass
phenotype
Concentration
Type of HS 1.0 mg/ml 0.1 mg/ml 0.01 mg/ml 0.001 mg/ml
heparin 83% (6)* 87% (61) 54% (11) 0% (8)
HS(FGF-2) 79% (14) 91% (33) 75% (8) 0% (8)
binding 79% (14) 47% (15)
non-bind. 0% (6) 7% (15)
HS(FGF-1) 25% (4) 10% (21)
HS 0% (8) 0% (8)
Percent of total embryos showing either a dorsal (see Fig. 2F) or
bifurcation (see Fig. 2D) bypass phenotype. Numbers in parenthesis indicate
total number of embryos. HS(FGF-2) is the full length GAG sidechain,
‘binding, non-bind.’ indicate the FGF-2 binding and non-FGF-2-binding
subfragments of the full length side chain.
*Concentration producing general toxic effect on embryo development.33/34. HSs were chronically present in the medium bathing the
exposed part of brain through to stage 40, when the optic pro-
jection was visualized with HRP histochemistry.
Heparin and full length FGF-2-binding HS sidechains
RGC axons normally follow a stereotyped pathway through the
diencephalon (the optic tract) and exhibit a smooth trajectory
as they cross the diencephalic-midbrain border to enter the
optic tectum (Fig. 2A,B; also see Chien et al., 1993; Harris et
al., 1987). Heparin treatment had little effect on axonal trajec-
tories within the optic tract, but disrupted axon behavior at the
tectal border causing them to veer sharply in dorsal or ventral
directions instead of continuing caudally to enter the tectum
(Fig. 2C,D). In the majority of cases, the entire retinal projec-
tion bypassed the tectum growing around either its anterior
margin (dorsal phenotype, for example see Fig. 2E,F,G), or
around both anterior and ventral margins (bifurcation
phenotype, see Fig. 2C,D; Table 1). To examine the involve-
ment of HS/FGF interactions in axonal target recognition we
used HS(FGF-2), an HS isolated from a murine neuroepi-thelial cell line that binds specifically to FGF-2 (Ford et al.,
1994). This HS(FGF-2) was recently identified as the gly-
cosaminoglycan sidechain of an embryonic form of perlecan
(Joseph et al., 1996), a well known FGF-2-binding HSPG
(Aviezer et al., 1994). The full length HS(FGF-2) impaired
axon targeting in a manner similar to heparin, causing over
90% of the projections to bypass the tectum (Fig. 2E,F and
Table 1). In dose-response experiments, concentrations of
heparin and HS(FGF-2) as low as 10 µg/ml caused aberrant
targeting (Table 1).
HS-treated axons did not arrest at the tectal border but
extended significantly further than control axons, often
crossing the dorsal midline via the posterior commissure to
invade the other side of the brain (40/53 heparin-treated and
26/31 HS(FGF-2)-treated embryos) suggesting that HS(FGF-
2) can enhance axon elongation. To examine this more directly,
HS(FGF-2) was tested for its ability to promote retinal neurite
extension in vitro. Previous results have shown that FGF-2
promotes neurite extension in dissociated retinal cultures
(McFarlane et al., 1995). When retinal neurons were cultured
in the presence of both FGF-2 and HS(FGF), an additional
increase in neurite length compared to FGF-2 treatment alone
was observed (Fig. 3). This indicates that HS(FGF-2) can
augment FGF-2-enhanced neurite outgrowth and suggests that
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Fig. 3. FGF-2-binding HS augments FGF-2 induced neurite
outgrowth in retinal cultures. Graph shows the mean length of the
longest neurite of retinal cells growing in 24 hour dissociated
cultures. Neurites in cultures treated with 20 ng/ml FGF-2 are
significantly longer compared to control (P<0.001) whereas addition
of 100 ng/ml FGF-2-binding HS (HS(FGF-2)) alone did not alter
neurite length compared to control (P>0.4). A combination of FGF-
2-binding HS with FGF-2 significantly increased neurite length
compared to FGF-2 treatment alone or control (P<0.001 for both
comparisons). n is the total number of neurites from 2-3 different
cultures, and error bars are s.e.m.
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Fig. 4. FGF-2-specific HSs interfere with 125I-FGF-2 binding to intact
brains. The ability of different carbohydrates to competitively
interfere with exogenous FGF-2 binding to brains dissected from
stage 40 embryos is displayed as % of counts per minute compared to
control experiment with no carbohydrates added. Whereas the FGF-2-
specific HSs (heparin and HS(FGF-2)) strongly inhibit 125I-FGF-2
binding to dissected brains (P<0.001, ***), HS(FGF-1) and a
commercially available HS (HS) only slightly reduce binding
(P<0.02, *). Neither chondroitin sulfate (CS) nor sucrose had any
effect. All carbohydrates were added at 0.1 mg/ml except for CS and
sucrose which were added at 1 mg/ml). n=6 brains for sucrose, CS,
and HS(FGF-2); and n=9 brains for heparin, HS(FGF-1), HS, and
controls pooled from 3 independent experiments. Error bars are s.e.m.HS(FGF-2) activates, rather than inhibits, FGFR signaling in
this system. 
FGF-2-binding HS fragments and FGF-2 non-binding
HSs
The full length HS(FGF-2) sidechains used in the above exper-
iments contain discrete domains that bind FGF-2 interspersed
with areas that do not (Nurcombe et al., 1993; Turnbull et al.,
1992). To test whether the biological activity associates with
the FGF-2-binding domains, the sidechains were fractionated
into 9 disaccharide, charge-matched units of FGF-2-binding
and non-binding subfragments. The FGF-2-binding fragments
potently induced targeting errors, similar in phenotype to that
found with full length HS(FGF-2) sidechains (Fig. 2G). In
contrast, the non-binding fragments had no effect on axon
growth (Fig. 2H and Table 1). To investigate whether the
bypass phenotype was specific to HSs that bind FGF-2, two
further full length HSs were tested: HS(FGF-1) which prefer-
entially binds FGF-1 and is derived from the same perlecan-
like HSPG as the HS(FGF-2) (Brickman et al., 1995; Ford et
al., 1994; Nurcombe et al., 1993), and a commercially available
HS with little FGF-2 binding capability (see below). Neither
of these HSs affected axonal pathfinding or targeting at con-
centrations where heparin and HS(FGF-2) showed dramatic
effects (Fig. 2I,J and Table 1).
To further investigate possible HS/FGF-2 interactions under-
lying the biological effects of HS, the ability of different HSs
to competitively interfere with exogenous FGF-2 binding to
Xenopus brains was evaluated. 125I-labeled FGF-2 (125I-FGF-
2) was added to live brains isolated from stage 40 embryos in
the presence or absence of different HSs and control carbohy-
drates. Only heparin and the FGF-2-binding HSs significantly
reduced 125I-FGF-2 binding (P<0.001, Fig. 4). Chondroitinsulfate and sucrose had no effect, while non-FGF-2-binding
and FGF-1-binding HSs slightly inhibited binding, possibly
reflecting the ability of all HSs to weakly bind FGFs. These
results confirm that the FGF-2-binding HSs used in this study
are able to out compete exogenous FGF-2 binding to the
endogenous low affinity HS sites in embryonic Xenopus brains.
Organization of neuroepithelium unaltered by
heparin treatment
Exogenously applied HSs could indirectly impair RGC axon
targeting by perturbing the neuroepithelial substrate through
which they grow. To examine effects of heparin treatment on
the neuroepithelium, cell viability (trypan blue; Hoechst
nuclear stain) and the expression of differentiated morpholog-
ical markers (anti-NCAM (Fig. 5A,B); anti-radial glia, data not
shown) were investigated. In all cases, similar staining patterns
were seen for heparin-treated and control brains. Furthermore,
cell counts of BrdU incorporation of dividing cells in the
forebrain showed no effect of heparin on cell proliferation
(33.9±2.8 per 10 m m cross-section in heparin-treated embryos
compared to 35.5±2.8 in controls, P>0.1, 36 sections each).
Nor did heparin treatment alter the organization, or number, of
newly formed axon tracts as visualized with anti-acetylated
tubulin (Fig. 5C,D). Thus, exogenously applied free heparin
does not appear to affect the gross organization of the neu-
roepithelium or the main axon tracts.
‘Pulse’ experiments define time of HS action
To determine the time course of HS action, HSs were added to
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Fig. 5. Gross organization of neuroepithelium is unchanged by
heparin treatment. Embryos were exposed to either control or heparin
solutions (0.1 mg/ml) at stage 33/34 and examined at stage 40.
(A,B) Confocal images of control (A) and heparin (B) treated brain
sections stained with anti-NCAM. NCAM is abundant in the neuropil
(Np) as well as in the neuroepithelium and is unaffected by heparin
treatment. Tec, tectum, exposed side is to the left, dorsal is up. Scale
bar, 50 m m. (C,D) Major axonal tracts are not changed by heparin
treatment as seen with anti-acetylated tubulin staining in wholemount
control (C) and heparin-treated (D) brains. tAC, tract of the anterior
commissure; tPC, tract of the posterior commissure; tPOC, tract of
the post-optic commissure. Dorsal is up, anterior to the left. Scale
bar, 100 m m.
Table 2. Effects of heparitinase treatment on axonal
growth, pathfinding and target recognition in the optic
projection
Phenotype*
Experiment Normal trajectory Shortened tract Aberrant growth
Early heparitinase 0/15 12/15 3/15
stage 32-37/38
Heparitinase+FGF-2 0/4 0/4 4/4
stage 32-37/38
Prolonged heparitinase 1/10 3/10 6/10
stage 32-40
Late heparitinase 1/12 2/12 9/12
stage 36/37-40
Prolonged suramin 0/17 17/17 0/17
stage 32-40
*Number of total embryos showing either a normal trajectory (see Fig.
6A), a short projection (see Fig. 6B) or aberrant growth with pathfinding
and/or target recognition errors (see Fig. 6C,D).exposed brains at different developmental stages for varying
durations. When heparin (0.1 mg/ml) was applied at early
stages (33/34) and washed out before stage 37/38, prior to the
arrival of the first RGC axons at the tectum, no influence on
target innervation was observed (0% mistargeting, n=6 optic
projections). However, if heparin was applied later, when axons
first begin to reach the tectum (stage 37/38), a strong tectal
bypass phenotype was observed (88% mistargeting, n=8 optic
projections). Thus, targeting errors occur only when heparin is
present at the time axons first encounter the tectum. These
results indicate a rapid mode of action for exogenously applied
heparin, arguing that HSs do not cause long-term changes in
the neuroepithelial substrate, but rather act on RGC axons
directly, or interfere with RGC axon-substrate interactions.
HS removal retards axon extension and impairs
pathfinding and targeting 
To test for an endogenous role for HSPGs in the formation of
the optic projection, native HSs were removed from the optic
tract by treatment of exposed brains with heparitinase. The
elimination of HS from the exposed neuroepithelium was
confirmed by HepSS-1 antibody staining (Fig. 1B). When
brains were treated with heparitinase (0.25-0.5 U/ml) during
the period of initial retinal axon growth through the dien-
cephalon (stages 32-37/38, approx. 13 hours), axons failed to
extend far along the optic tract giving rise to abnormally shortprojections (Fig. 6B; Table 2). To control for possible non-
specific effects of heparitinase on the neuroepithelial substrate,
the gross organization of the neuroepithelium was examined
using Hoechst nuclear stain and anti-NCAM staining and
found to be normal (data not shown). In addition, no evidence
was found for increased apoptosis in the retina following
heparitinase treatment (data not shown). When brains were
treated with heparitinase for a longer duration (stages 32-40,
approx. 26 hours) axons continued to extend but, interestingly,
made gross errors in pathfinding and targeting (Table 2;
phenotype similar to that shown Fig. 6C). When heparitinase
was applied later in development during the period when
retinal axons first invade the tectum (stages 36/37-40, approx.
16 hours; Table 2), axons showed a strong tectal bypass
phenotype (Fig. 6D). These results indicate that endogenous
HSs play a role in promoting axon elongation through the optic
tract and suggest that they also help in relaying or patterning
guidance information in the neuroepithelial substrate.
Added FGF-2 overcomes heparitinase-induced
growth inhibition 
FGF-2 is present in the developing optic pathway and can
stimulate the extension of retinal neurites in vitro, suggesting
that in vivo FGF-2 promotes the extension of retinal axons
through the optic tract (McFarlane et al., 1995). Suramin (10
m M), a drug that prevents growth factors from binding to their
receptors (Voogd et al., 1993), produced significantly shorter
projections compared to control (Table 2), indicating that
normal RGC axonal growth through the diencephalon requires
the activity of one or more growth factors. Since HS is a crucial
co-factor in FGF-2 signaling, we asked whether the retarded
axonal extension observed with the enzymatic removal of
endogenous HSs might result from disabling extracellular
FGF-2 activity. FGF-2 (100 ng/ml) and heparitinase (0.25-0.5
U/ml) were added simultaneously to exposed optic tracts at
stage 33/34 and assayed at stage 37/38. Under these conditions,
the length of the optic projections was similar to controls (Fig.
6C; Table 2), demonstrating that activation of FGF signaling
can restore normal rates of axon extension. The directional
growth of these FGF-2-restored axons, however, was extremely
aberrant in the diencephalon similar to those caused by
prolonged heparitinase treatment alone, and they continued to
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Fig. 6. Effects of enzymatic removal of native HS on
retinal axon growth. (A) Control brain showing a
normal optic projection at stage 37/38. (B) ‘Early’
heparitinase treatment during the period of axon
extension through the optic tract, stage 32 to 37/38,
causes abnormally short projections that fail to reach
the tectum. (C) When FGF-2 (100 ng/ml) is added
concomitant with heparitinase, the growth inhibition is
alleviated and axons extend to normal lengths.
However, many pathfinding errors occur with axons
veering off the optic tract into the telencephalon and
diencephalon (arrowheads) and axons bypass the
tectum (arrow). (D) ‘Late’ heparitinase treatment
during the period of initial tectal invasion, stage 36/37
to 40, causes the bypass phenotype typical of defective
target recognition. Tel, telencephalon; Di,
diencephalon; Tec, tectum; ot, optic tract; arrows depict
anterior border of the tectum. Scale bar, 200 m m.exhibit targeting errors, as seen with exogenous FGF-2 appli-
cation alone (Fig. 6C; McFarlane et al., 1995). 
DISCUSSION
The results presented here strongly indicate that HSs are
important in axon growth and guidance. First, FGF-2-binding
HSs are potent inhibitors of target recognition and can com-
petitively inhibit the binding of FGF-2 to embryonic Xenopus
brains. Second, HSs are present in the embryonic diencephalon
where retinal axons grow, and absent in the rostral tectum, a
pattern that parallels that of FGF-2 (McFarlane et al., 1995).
Third, digestion of these endogenous HSs produces dramatic
defects in axon growth, navigation and targeting. Fourth,
exogenous FGF-2 can overcome the growth inhibitory effect
of HS removal.
Exogenous HS causes marked, often contrasting, effects on
neurite outgrowth in vitro (Dow et al., 1991; Giuseppetti et al.,
1994; Haugen et al., 1992a; Isahara and Yamamoto, 1995;
Verna et al., 1989). This diversity of action could be due to the
ability of HS to competitively interfere with the activity of a
variety of native HS-binding molecules. In showing that ex-
ogenously applied HSs act rapidly and reversibly, without
causing gross defects in neuroepithelial organization, our
results argue against a slow mode of action such as changes in
gene expression, and are consistent with the idea that HS exerts
its action in the developing Xenopus visual system by perturb-
ing the interaction of HS-binding molecules with their
receptors in the growth cones. In a similar fashion, a different
class of glycosaminoglycan, chondroitin sulfate (CS), is
thought to cause its diverse effects through competitively inter-
fering with CS-binding molecules (Emerling and Lander,
1996). Several lines of evidence support FGF-2 as a candidate
HS-binding molecule whose function is disrupted by perturb-
ing HS activity. (1) The pattern of native HS immunostaining
is similar to FGF-2 (McFarlane et al., 1995) in that it is strong
in the optic tract and absent in the tectum. (2) The tectal bypassphenotype is similar to that caused by direct perturbations of
FGF signaling. (3) Only FGF-2-binding HS and fragments
cause the bypass phenotype. (4) Axon growth is retarded in the
optic tract by removal of native HS and FGF-2 can relieve this
growth inhibition; blocking FGFR function in RGCs similarly
retards axon growth (McFarlane et al., 1996). (5) HS augments
FGF-2-stimulated neurite outgrowth. Finally, de-N-sulfated
heparin also caused mistargeting (data not shown) which
agrees with studies showing sulfation to be necessary for HS
to bind FGF-2 (Rusnati et al., 1994) but that N-sulfation specif-
ically is not involved (Ornitz et al., 1995). 
Our previous studies have indicated that axon mistargeting
can result from either a sustained increase or decrease in FGFR
activity in retinal growth cones (McFarlane et al., 1995, 1996).
This led to a model based on the idea that retinal growth cones
respond to changes in FGFR signaling that occur at the tectal
border (McFarlane et al., 1996). Since levels of FGF-2
diminish sharply at the tectal border, we suggested that this
might provide the trigger for such a signaling change, which,
in turn, could activate a molecular program responsible for
target entry. The observation that HS immunoreactivity is
localized in a like fashion suggests that native HS and FGF-2
together could participate in demarcating the optic tract where
axons grow, from the target where axons arborize, and is in line
with the idea that regulation of FGFR signaling at the tectal
border is a key factor in target recognition. The mistargeting
of axons after HS and hepartitinase treatment is also consistent
with this model. HS(FGF-2) could potentially sustain high
levels of FGFR activation, like exogenous FGF-2, rendering
retinal growth cones insensitive to changes in external ligand
concentration. Indeed, HS(FGF-2) seems to be stimulatory in
its action in this system since it augments FGF-enhanced
neurite outgrowth in vitro and does not inhibit axon extension
in vivo. In contrast, removal of endogenous HS by heparitinase
treatment, which presumably decreases FGFR function, similar
to the dominant negative FGFR, would likewise render growth
cones unable to register changes in ligand concentration.
The exact mechanism of HS requirement for FGF activity has
2428 A. Walz and othersnot been elucidated. HSs can stimulate as well as inhibit FGF-
2 function, so the mechanism is not straight forward (Guimond
et al., 1993; Hondermarck et al., 1992). Recent models attribute
the role of the HS cofactor to its ability to present multiple FGFs
and thus bring about receptor dimerization (Schlessinger et al.,
1995; Spivak-Kroizman et al., 1994). In addition, several studies
have indicated that HSs can bind directly to specific FGFRs (Kan
et al,. 1993; Seddon et al., 1995; Wang et al., 1995) and even
activate FGFRs without FGF ligand (Gao and Goldfarb, 1995).
Furthermore, HSPGs can dynamically regulate their HS
sidechains and, in so doing, can change their peptide-binding
preferences (Nurcombe et al., 1993). Comparison of the disac-
charide sequences of the FGF-2- and FGF-1-binding HS
sidechains has demonstrated the existence of distinct motifs that
confer differential binding specificity (V. Nurcombe and col-
leagues, unpublished data), a finding that might help to explain
the diverse action of HSs from different sources. Thus, HSPGs
in vivo probably function to regulate precisely the availability
and activity of specific FGF ligands with specific high affinity
receptors. Interestingly, the specific FGF-2-binding HS used in
the current study has recently been shown to specifically interact
with the murine FGFR-1 (Brickman et al., 1995). Thus, the
bypass phenotype seen with the exogenous application of this
specific HS may result from it uniquely interfering with the
endogenous interaction of FGF-2 with only one of the four
families of FGFRs. FGFR-1 is present in the developing
Xenopus eye primordium (Friesel and Dawid, 1991; M. Zuber
and C. E. Holt, unpublished data), raising the possibility that the
interaction between FGF-2 and FGFR-1 is specifically required
for retinal axon target recognition.
One of the striking features of the bypass phenotype induced
by HS(FGF-2) is its robust penetrance. Almost the entire pop-
ulation of retinal axons veer aberrantly around the tectum and
91% of brains treated at 0.1 mg/ml exhibit the phenotype. This
degree of penetrance is similar to that obtained with exogenous
FGF-2 but is markedly higher than that seen with expression
of the dominant negative FGFR where approximately 50% of
the axons show targeting errors. This might reflect the fact that
‘overexpression’ phenotypes tend to be more severe than single
knockouts of the same protein (Chiba et al., 1995; Nose et al.,
1994). Alternatively, exogenous HSs and heparitinase might
disrupt not just FGFR signaling but also other molecules
important for target recognition.
The short projections observed after early heparitinase
treatment indicate that native HSs play a role in promoting
RGC axon elongation through the optic tract. A possible expla-
nation for this phenotype is that in the absence of HSs, en-
dogenous FGF-2 may be unable to adequately activate the high
affinity FGFR to stimulate normal axonal elongation rates.
Indeed, when FGFR function is blocked, RGC axons grow at
a markedly slower rate (McFarlane et al., 1996). In addition,
the HS staining pattern co-localizes with the previously
described expression of FGF-2 in the optic pathway indicating
that the elements of functional FGF-2 signaling are present for
RGC axons growing through the ventral and mid-dien-
cephalon. Furthermore, applying an excess of exogenous FGF-
2 to HS-free brains results in optic projections similar in length
to control projections. This last finding may reflect the ability
of excess FGF-2 to cause receptor dimerization sidestepping
the function of the low affinity HS receptor (Roghani et al.,
1994).In addition to promoting FGF-2-dependent axon growth in
the optic tract, endogenous HSs appear to impart directional
information to growing axons. Our results show that when
RGC axons are induced to grow in a HS-depleted diencephalon
the majority of axons exhibit striking errors in pathfinding.
This misrouting phenotype is not seen with exogenous HS
where the optic tract trajectories appear normal, nor with any
treatments that interfere specifically with FGF/R signaling.
This suggests the possibility that native HSs in the dien-
cephalon bind and localize the activity of (non-FGF) guidance
molecule(s) that specifically identify the optic tract neuro-
epithelium. Indeed, heparin is known to bind and thus poten-
tially regulate the activities of molecules that guide axons such
as netrin and collapsin/semaphorin (Raper and Kapfhammer,
1990; Serafini et al., 1994). In addition, HSs are required for
NCAM-mediated adhesion of retinal cells and may act as an
alternative receptor for laminin and other ECM molecules in
the CNS (Cole et al., 1986; Haugen et al., 1992a,b). 
Two of the HSs that had distinct effects in this study,
HS(FGF-1) and HS(FGF-2), were isolated from the same
perlecan variant. The developmentally regulated glycosylation
changes of this HSPG in the developing mouse brain are
thought to switch the responsiveness of cells to external growth
factors (Nurcombe et al., 1993). A similar type of mechanism
may also exist during axon navigation such that an axon’s
responsiveness to certain guidance cues depends on the type of
cofactor present. It is not known which HSPGs might be
playing a role in Xenopus visual system development.
Perlecans are large ECM proteoglycans that are present in the
basal lamina of the mouse CNS (Joseph et al., 1996). Our data
suggest that HS is not just restricted to the basal lamina in the
Xenopus optic tract since retinal axons are also immunoposi-
tive. The integral membrane HSPGs, syndecans, are potential
candidates because syndecans 2 and 3 have recently been
shown to be expressed in a complementary pattern in the devel-
oping Xenopus brain with syndecan 2 defining the dien-
cephalic/midbrain boundary (Teel and Yost, 1996). In addition,
syndecans can support FGF-2-FGFR1 interactions and
signaling (Steinfeld et al., 1996).
Our results suggest a crucial role for HSPGs in the estab-
lishment of the retinotectal projection, both during axon
elongation through the diencephalon and subsequent target
recognition in the tectal area. HS activity appears to stem, at
least in part, from its participation in FGF-2 signaling. In the
future it will be important to identify the individual HSPG
species involved and to determine their specific actions in the
development of the visual projection.
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